Clinical Trials
2
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Recruiting
2
100.0%
No approval data available
- Extracellular vesicles (EVs) from diverse sources including MSCs, immune cells, plants, and milk show therapeutic potential across tissue repair, immune modulation, oncology, and neurological disorders. - As of April 2026, no EV therapeutic product has received formal marketing approval; only 9 industry-sponsored candidates have entered registered clinical trials, with one in Phase III. - Japan's PMDA released the world's first national-level official technical guideline for EV therapeutics in August 2024, while China's CDE formally incorporated EVs into the ATMP framework in June 2025. - Key translational bottlenecks include insufficiently defined therapeutic mechanisms, lack of standardized manufacturing and quality control, and fragmented global regulatory frameworks requiring harmonization.
- The exosome therapeutics field is experiencing significant growth with preparations underway for the first clinical trials and substantial investment through partnerships and pipeline acquisitions. - Industry leaders including Evox Therapeutics, Aruna Bio, Codiak Biosciences, and Capricor Therapeutics are advancing end-to-end drug development from discovery to scalable GMP-grade manufacturing. - Key challenges remain in establishing robust characterization techniques, quality assurance, and regulatory compliance as companies work to deliver targeted therapeutics to clinical and commercial reality.
- Despite 32 approved gene therapies globally, the industry faces significant challenges in safety, efficacy, and affordability, prompting development of novel delivery systems beyond traditional viral vectors. - Companies are advancing non-viral delivery platforms including exosomes, lipid nanoparticles, and hydrophilic nanoparticles that offer cost-effective alternatives with reduced immunogenicity and potential for repeat dosing. - Next-generation gene editing technologies like Prime Editing and CRISPR variants are emerging as more precise alternatives to traditional CRISPR-Cas9, with Prime Medicine's PM359 for chronic granulomatous disease advancing to clinical trials.
